MetaCap

Cabot Corporation (CBT)

NYSE: CBTIndustrialsMajor ChemicalsUSD

70.48-2.35 (-3.23%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CBT stock chart

Technical analysis

Key statistics

All statistics
Dividend yield
2.68% ($0.00)
Ex-dividend date
Aug 28, 2026
52-week range
60.68 – 94.53
Day range
70.44 – 73.32
Volume / Avg
475.86K / 392.73K
Beta
—

52-week range

$60.68$94.53

CBT stock today

On Nov 20, CBT ended the session at $70.48, shedding $2.35 (3.23%), versus the S&P 500's 3.70% decline. Shares are 25.4% below their 52-week high of $94.53, set on Jun 26, 2026 and 16.2% above the 52-week low of $60.68, in the middle of the past year's range. CBT is up 6.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 14.2%.

At 17.5x trailing earnings, Cabot trades below the peer-group median of 27.6x. Its forward P/E of 9.5x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Cabot

Company profile

Cabot Corporation operates as a specialty chemicals and performance materials company. It operates through two segments, Reinforcement Materials and Performance Chemicals. The company offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.

Industry
Major Chemicals
CEO
Ms. Erica J. McLaughlin CPA
Headquarters
Boston, MA
Employees
4,064

Financial highlights

Full financials

In fiscal 2026, Cabot generated $3.74 billion in revenue, up 0.8% from fiscal 2025. Net income was $213.0 million (-35.6% year over year), for a net margin of 5.7% versus a median of 8.9% in the prior 5 years. Gross margin was 21.6% (down from 25.3%) and operating margin 12.7%.

Cabot annual revenue, net income and EPS
Fiscal yearFY 2026FY 2025FY 2024FY 2023FY 2022
Revenue$3.74B$3.71B$3.99B$3.93B$4.32B
Growth+0.83%-7.04%+1.60%-9.03%+26.75%
Net income$213.00M$331.00M$380.00M$445.00M$209.00M
EPS (diluted)$4.02$6.02$6.72$7.73$3.62

Analyst forecast

Forecast

Consensus (6 analysts)

buy

Avg. price target

$85.33+21.07%

  • Strong buy 0
  • Buy 2
  • Hold 3
  • Sell 0
  • Strong sell 1

Target range

Low $68.00High $95.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 2, 2026
EPS actual vs est.
$1.70 vs $1.55
Surprise
+9.68%

Dividends

Dividend history
Annual dividend
$0.00
Last payment
$0.473
Ex-dividend date
Aug 28, 2026

CBT news

All CBT news

Cabot peers

Industrials sector
CBT peer companies
CompanyPrice% ChgMarket capCompare
AVNTAvient Corporation42.84-1.13%$3.93Bvs CBT
WDFCWD-40 Company218.68-0.68%$2.93Bvs CBT
PRMPerimeter Group Inc.27.55-5.97%$4.51Bvs CBT
VVVValvoline Inc.36.25-1.60%$4.62Bvs CBT
KWRQuaker Houghton147.48-2.33%$2.54Bvs CBT
MEOHMethanex Corporation61.18-3.01%$4.73Bvs CBT
SXTSensient Technologies Corporation113.85-2.22%$4.85Bvs CBT
CECelanese Corporation45.01-5.04%$4.94Bvs CBT

Indexes, lists and sector

Cabot stock FAQ

What is Cabot's stock price today?

CBT last traded at $70.48 as of Nov 20, 4:00 PM EST, down 3.23% on the day. Prices are delayed at least 15 minutes.

Does Cabot pay a dividend?

Yes. Cabot pays $0.00 per share annually, a 2.68% yield. The most recent dividend of $0.473 had an ex-dividend date of Aug 28, 2026.

What is CBT's P/E ratio?

CBT trades at a trailing P/E ratio of 17.53 and a forward P/E of 9.50, compared with a median of 27.6 for its closest peers.

Who is Cabot's CEO?

Ms. Erica J. McLaughlin CPA is the chief executive officer of Cabot Corporation, which has about 4,064 employees.

Has CBT ever split its stock?

Yes. The most recent CBT stock split was a 2-for-1 split on Mar 25, 1996, one of 3 splits on record.

What is the CBT 52-week high?

The 52-week high for CBT is $94.53 and the 52-week low is $60.68. The stock is currently 25.4% below its high.

Compare CBT